Investigators examined use of tapentadol, which has µ-opioid receptor agonist and norepinephrine reuptake inhibitor activity, for moderate-to-severe chronic osteoarthritis knee pain or low back pain.
There were no significant differences between tapentadol ER and a placebo or oxycodone CR in changes from baseline to endpoint in blood pressure or heart rate.
Read the Clinical Advisor on pain.
Related Articles on Analgesics for Pain Management:
Dr. Bruce Nicholson Presents Four Strategies to Tackle Post-Op Pain
Study: Certain Analgesia Decreases Phantom Limb Pain
Drug Response Profile Dependent on Pain Mechanism and Opioid Type
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
